Pharmacogenetic algorithm for individualized controlled ovarian stimulation in assisted reproductive technology...

Area of Science:

• Reproductive Endocrinology
• Clinical Genetics
• Assisted Reproductive Technologies

Background:

• Controlled ovarian stimulation (COS) is essential for in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) success.
• Predicting ovarian response to COS is challenging, with some patients exhibiting suboptimal responses despite normal ovarian reserve biomarkers (e.g., AFC, AMH).
• This suboptimal response suggests that factors beyond traditional biomarkers, potentially including genetic influences on ovarian sensitivity to gonadotropins, play a significant role.

Purpose of the Study:

• To explore the role of gene polymorphisms in modulating ovarian response to COS.
• To investigate the potential of a pharmacogenetic approach to personalize COS protocols.
• To enhance the prediction of oocyte yield and optimize treatment strategies in assisted reproduction.

Main Methods:

• Analysis of gene polymorphisms related to reproductive function and ovarian response.
• Correlation of genetic profiles with ovarian sensitivity to exogenous gonadotropins.
• Evaluation of the potential for pharmacogenetic profiling in clinical decision-making for COS.

Main Results:

• Individual variability in COS response may be explained by genetic factors.
• Gene polymorphisms can influence ovarian sensitivity to exogenous gonadotropins.
• Pharmacogenetics offers a promising avenue for tailoring COS protocols.

Conclusions:

• Understanding genetic variations can improve the management of patients undergoing COS.
• A pharmacogenetic approach may enable personalized gonadotropin selection and dosage optimization.
• This strategy has the potential to increase IVF/ICSI success rates and reduce time-to-pregnancy.